Form 8-K - Current report

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 4, 2023

BIOPLUS ACQUISITION CORP.

(Exact name of registrant as specified in its charter)

Cayman Islands	001-41116	98-1583872
(State or other jurisdiction	(Commission File Number)	(I.R.S. Employer
of incorporation)		Identification No.)

260 Madison Avenue

Suite 800

New York, New York

10026

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including area code (212) 287-4092

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Units, each consisting of one Class A Ordinary Share and one-half of one Redeemable Warrant	BIOSU	The Nasdaq Stock Market LLC
Class A Ordinary Share, par value $0.0001 per share	BIOS	The Nasdaq Stock Market LLC
Warrants, each exercisable for one Class A Ordinary Share for $11.50 per share	BIOSW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01. Entry into a Material Definitive Agreement.

As previously disclosed, on May 2, 2023, BioPlus Acquisition Corp., a Cayman Islands exempted company (“BIOS” or the “Company”), Guardian Merger Subsidiary Corp., a Delaware corporation and a direct wholly owned subsidiary of BIOS (“Merger Sub”), and Avertix Medical, Inc. (f/k/a Angel Medical Systems, Inc.), a Delaware corporation (“Avertix”), and, solely with respect to Section 3.03(b) and Section 7.21 of the Business Combination Agreement (as defined below), BioPlus Sponsor LLC, a Cayman Islands limited liability company (the “Sponsor”), entered into a business combination agreement and plan of reorganization (the “Business Combination Agreement”), pursuant to which Merger Sub will merge with and into Avertix (the “Merger”), with Avertix surviving the Merger as a direct wholly owned subsidiary of BIOS.

On October 4, 2023, pursuant to Section 9.01(a) of the Business Combination Agreement, the parties to the Business Combination Agreement entered into a Termination and Release Agreement (the “Termination Agreement”) to terminate the Business Combination Agreement (the “Termination”). The Termination Agreement also automatically terminates ancillary documents to the Business Combination Agreement (the “Ancillary Documents”), including certain stockholder support agreements, by and among BIOS, Avertix and certain stockholders of Avertix (the “Stockholder Support Agreements”), and the sponsor support agreement, by and among BIOS, the Sponsor and Avertix (the “Sponsor Support Agreement”). Additionally, the Termination Agreement provides for a mutual release of claims among the parties and their affiliates.

As a result of the Termination, the Business Combination Agreement is of no further force and effect, with the exception of specified provisions set forth in the Termination Agreement, and all provisions of the Ancillary Documents, including provisions of any such Ancillary Document that by their terms would otherwise have survived the termination of such Ancillary Document, is of no further force and effect.

The foregoing descriptions of the Business Combination Agreement, the Termination Agreement and the Ancillary Documents do not purport to be complete and are qualified in their entirety by the terms and conditions of, respectively, (i) the Business Combination Agreement, a copy of which was previously filed as Exhibit 2.1 to BIOS’ Current Report on Form 8-K filed with the Securities and Exchange Commission (“SEC”) on May 3, 2023, (ii) the Termination Agreement, a copy of which is filed with this Current Report on Form 8-K as Exhibit 10.1, and the terms of which are incorporated by reference herein and (iii) the Stockholder Support Agreements and the Sponsor Support Agreement, copies of which were previously included as Exhibits 10.3 and 10.4 to BIOS’ Current Report on Form 8-K filed with the SEC on May 3, 2023.

Item 1.02. Termination of Material Definitive Agreement.

The information set forth in Item 1.01 above is hereby incorporated by reference into this Item 1.02.

Item 8.01 Other Events.

In view of the termination of the Business Combination Agreement, BIOS determined that it would be unable to consummate an initial business combination within the time period in accordance with the provisions of its Amended and Restated Memorandum and Articles of Association, as amended (the “Charter”) and BIOS intends to dissolve and liquidate in accordance with the provisions of its Charter.

BIOS expects to redeem all of its Class A ordinary shares that were included in the units issued in the Company’s initial public offering (“Public Shares”) for an estimated redemption price of approximately $10.79 per share (the “Redemption Amount”) after the payment of taxes and dissolution expenses. Record holders will receive their pro rata portion of the proceeds of the trust account by delivering their Public Shares to Continental Stock Transfer & Trust Company, the Company’s transfer agent. Beneficial owners of Public Shares held in “street name,” however, will not need to take any action in order to receive the Redemption Amount. The redemption of the Public Shares is expected to be completed within ten business days after October 4, 2023.

The Sponsor has agreed to waive its redemption rights with respect to its outstanding Class B ordinary shares issued prior to the Company’s initial public offering and the Class A ordinary shares contained in the units issued in a private placement concurrent with the initial public offering.

There will be no redemption rights or liquidating distributions with respect to the Company’s warrants, which will expire worthless.

On October 4, 2023, BIOS issued a press release announcing the termination of the Business Combination Agreement and its intent to liquidate. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibits

The following exhibits are filed herewith:

Exhibit No.		Description of Exhibits
10.1		Termination and Release Agreement, dated October 4, 2023, by and among BioPlus Acquisition Corp., Guardian Merger Subsidiary Corp., Avertix Medical, Inc., and BioPlus Sponsor LLC.
99.1		Press Release dated October 4, 2023.
104.1		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: October 4, 2023

BioPlus Acquisition Corp.

By:	/s/ Ross Haghighat
	Name:	Ross Haghighat
	Title:	Chief Executive Officer and Chief Financial Officer

Exhibit 10.1

tERMINATION AND RELEASE AGREEMENT

THIS TERMINATION AND RELEASE AGREEMENT (this “Termination Agreement”) is entered into and made effective as of October __, 2023 (the “Termination Date”), by and among: BioPlus Acquisition Corp., a Cayman Islands exempted company (“Acquiror”); Guardian Merger Subsidiary Corp., a Delaware corporation and a direct wholly owned Subsidiary of Acquiror (“Merger Sub”); Avertix Medical, Inc. (f/k/a Angel Medical Systems, Inc.), a Delaware corporation (the “Company”); and BioPlus Sponsor LLC, a Cayman Islands limited liability company (the “Sponsor”). Acquiror, Merger Sub, the Company and the Sponsor are sometimes referred to herein, individually, as a “Party” and, collectively, as the “Parties”. Capitalized terms used but not defined herein shall have the meanings assigned to such terms in the BCA (as defined below)

Recitals

Whereas, the Parties entered into that certain Business Combination Agreement and Plan of Reorganization, dated as of May 2, 2023 (the “BCA”); and

Whereas, the Parties desire to terminate the BCA and all other Transaction Documents in accordance with Section 9.01(a) thereof as more fully set forth herein.

Agreement

Now, Therefore, in consideration of the mutual agreements contained herein and for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

1. Termination of BCA. Pursuant to and in accordance with 9.01(a) of the BCA, Acquiror and the Company hereby agree by mutual consent to terminate the BCA and, consequently, all other Transaction Documents, effective as of the date hereof. Pursuant to and in accordance with Section 9.02 of the BCA, the BCA and, consequently, all other Transaction Documents, have become void and shall have no effect.

2. Waiver; Release.

(a) Acquiror, Merger Sub and the Sponsor, for themselves, and on behalf of each of their respective affiliates, equity holders, partners, joint venturers, lenders, administrators, representatives, shareholders, parents, subsidiaries, officers, directors, attorneys, agents, employees, legatees, devisees, executors, trustees, beneficiaries, insurers, predecessors, successors, heirs and assigns (the “Acquiror Releasing Parties”), hereby absolutely, forever and fully release and discharge the Company and the Company’s affiliates and respective present and former direct and indirect equity holders, directors, officers, employees, predecessors, partners, stockholders, joint venturers, administrators, representatives, affiliates, attorneys, agents, brokers, insurers, parent entities, subsidiary entities, successors, heirs, and assigns, and each of them (the “Company Released Parties”), from all claims, contentions, rights, debts, liabilities, demands, accounts, reckonings, obligations, duties, promises, costs, expenses (including, without limitation, attorneys’ fees and costs), liens, indemnification rights, damages, losses, actions, and causes of action, of any kind whatsoever, whether due or owing in the past, present or future and whether based upon contract, tort, statute or any other legal or equitable theory of recovery, and whether known or unknown, suspected or unsuspected, asserted or unasserted, fixed or contingent, matured or unmatured, with respect to, pertaining to, based on, arising out of, resulting from, or relating to the BCA, the Transaction Documents, and the Merger, including the events leading to the abandonment of the Merger and the termination of the BCA and the other Transaction Documents (the “Acquiror Released Claims”); provided, however, that this Section 2(a) shall not impact, limit, restrict, or waive any terms, provisions, rights or obligations set forth in this Termination Agreement or the Confidentiality Agreement.

(b) The Company for itself, and on behalf of each of the Company’s affiliates, equity holders, partners, joint venturers, lenders, administrators, representatives, stockholders, parents, subsidiaries, officers, directors, attorneys, agents, employees, legatees, devisees, executors, trustees, beneficiaries, insurers, predecessors, successors, heirs and assigns (the “Company Releasing Parties”), hereby absolutely, forever and fully release and discharge Acquiror, Merger Sub and the Sponsor and their affiliates and each of their respective present and former direct and indirect equity holders, directors, officers, employees, predecessors, partners, stockholders, joint venturers, administrators, representatives, affiliates, attorneys, agents, brokers, insurers, parent entities, subsidiary entities, successors, heirs, and assigns, and each of them (the “Acquiror Released Parties”), from all claims, contentions, rights, debts, liabilities, demands, accounts, reckonings, obligations, duties, promises, costs, expenses (including, without limitation, attorneys’ fees and costs), liens, indemnification rights, damages, losses, actions, and causes of action, of any kind whatsoever, whether due or owing in the past, present or future and whether based upon contract, tort, statute or any other legal or equitable theory of recovery, and whether known or unknown, suspected or unsuspected, asserted or unasserted, fixed or contingent, matured or unmatured, with respect to, pertaining to, based on, arising out of, resulting from, or relating to the BCA, the Transaction Documents, and the Merger, including the events leading to the abandonment of the Merger and the termination of the BCA and the other Transaction Documents (the “Company Released Claims,” and together with the Acquiror Released Claims, the “Released Claims”); provided, however, that this Section 2(b) shall not impact, limit, restrict, or waive any terms, provisions, rights or obligations set forth in this Termination Agreement or the Confidentiality Agreement.

(c) Acquiror, Merger Sub and the Sponsor, on behalf of itself and the Acquiror Releasing Parties, hereby covenants to the Company Released Parties not to directly or indirectly encourage or solicit or voluntarily assist or participate in any way in the filing, reporting or prosecution by Acquiror, Merger Sub, the Sponsor or any of the Acquiror Releasing Parties of a suit, arbitration, mediation, or claim (including a third party or derivative claim) against any of the Company Released Parties relating to any Acquiror Released Claim.

(d) The Company, on behalf of itself and the Company Releasing Parties, hereby covenants to Acquiror Released Parties not to directly or indirectly encourage or solicit or voluntarily assist or participate in any way in the filing, reporting or prosecution by the Company or the Company Releasing Parties of a suit, arbitration, mediation, or claim (including a third party or derivative claim) against any of the Acquiror Released Parties relating to any Company Released Claim.

(e) Each Party acknowledges and understands that there is a risk that subsequent to the execution of this Termination Agreement, such Party may discover, incur or suffer Released Claims that were unknown or unanticipated at the time of the execution of this Termination Agreement, and which, if known on the date of the execution of this Termination Agreement, might have materially affected such Party’s decision to enter into and execute this Termination Agreement. Each Party expressly waives any rights it may have under any statute or common law principle under which a general release does not extend to claims which such Party does not know or suspect to exist in its favor at the time of executing the release. Each Party further agrees that by reason of the releases contained herein, such Party is assuming the risk of such unknown Released Claims and agrees that this Termination Agreement applies thereto.

3. Non-Disparagement. For the consideration described herein, each Party agrees that the other Parties’ goodwill and reputation are assets of great value which were obtained through great costs, time and effort. Therefore, each Party agrees that they shall not in any way, directly or indirectly, disparage, criticize, deride, cast in a negative light, libel or defame any of the other Parties, their owners, directors, officers, affiliates or subsidiaries, their respective business or business practices, services, or employees, nor engage in any activity of any nature which in any way results in any disruption to the routine business of any of the other Parties, or which is damaging to the reputation of any of the other Parties, or which is otherwise detrimental to any of the other Parties’ business activities or relationships. Each Party understands and agrees that non-disparagement is a material term of this Termination Agreement and that any breach of this provision will constitute a material breach of this Termination Agreement.

4. Mutual Representations. Each Party represents and warrants to the other Party that it has complied in all material respects with Section 7.01 of the BCA. Each Party hereby represents and warrants to each other Party that (a) such Party has full corporate power and authority to execute and deliver this Termination Agreement, (b) the execution and delivery of this Termination Agreement, the termination of the BCA and the other Transaction Documents have been duly and validly approved by the board of directors of such Party, (c) no other corporate proceedings on the part of such Party are necessary to approve this Termination Agreement or the termination of the BCA or any other Transaction Document, and (d) this Termination Agreement has been duly and validly executed and delivered by such Party (assuming due authorization, execution and delivery by the other Party) and constitutes a valid and binding obligation of such Party, enforceable against such Party in accordance with its terms (except in all cases as such enforceability may be limited by the Remedies Exceptions).

5. Public Announcements. Acquiror shall issue a Current Report on Form 8-K relating to this Termination Agreement hereto no later than the fourth (4^th) Business Day after the date hereof (the “Form 8-K”). Thereafter, and except for (a) such Form 8-K filing, (b) disclosure or communication required by applicable Law or stock exchange rule or (c) in response to any request by any Governmental Authority, no Party shall issue any press release, public statement or public filing with respect to the other Parties, the transactions contemplated by the BCA and/or this Termination Agreement, without the prior written consent of Acquiror, in the case of the Company, or the Company in the case of Acquiror, Merger Sub and the Sponsor. Notwithstanding anything to the contrary in the foregoing, nothing set forth in this Section 5 shall prohibit: (i) Acquiror from making similar disclosures as set forth in the Form 8-K in other future filings, proxy statements or other documents filed with, or disclosed with, the SEC; or (ii) the Company informing the Company’s stockholders of the terms and conditions of this Termination Agreement and otherwise disclose that the BCA has been terminated.

6. Confidential Information. Acquiror and the Sponsor shall promptly return to the Company or destroy all Evaluation Material (as defined in the Confidentiality Agreement) of the Company subject to and in accordance with the terms of the Confidentiality Agreement.

7. Governing Law; Consent to Jurisdiction; Waiver of Trial by Jury; Trust Account Waiver. Section 6.03, Section 10.07, and Section 10.08 of the BCA are hereby incorporated by reference into this Termination Agreement mutatis mutandis.

8. Headings. The headings in this Termination Agreement are for convenience only and shall not be considered a part of or affect the construction or interpretation of any provision of this Termination Agreement.

9. Entire Agreement. Except for the obligations or provisions of the BCA, in each case, expressly deemed to survive under terms and conditions of this Termination Agreement, this Termination Agreement constitutes the entire agreement of the Parties with respect to the subject matter hereof, and supersedes all other prior agreements and understandings, both written and oral, between the Parties, or any of them, with respect to the subject matter hereof and thereof, including, without limitation, the BCA and the Transaction Documents.

10. Third Party Beneficiaries. Each Party acknowledges and agrees that each of the Company Released Parties and the Aquiror Released Parties (collectively, the “Released Parties”) are express third party beneficiaries of the releases and covenants contained in Section 2 and Section 3 of this Termination Agreement and are entitled to enforce rights under such Sections to the same extent that such Released Parties could enforce such rights if they were a party to this Agreement. Except as provided in the preceding sentence, there are no third party beneficiaries to this Termination Agreement, and this Termination Agreement is not otherwise intended to and shall not otherwise confer upon any Person other than the Parties any rights or remedies hereunder.

11. Severability. If any term or other provision of this Termination Agreement is invalid, illegal or incapable of being enforced by any rule of law, or public policy, all other conditions and provisions of this Termination Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions contemplated by this Termination Agreement are not affected in any manner materially adverse to any party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the Parties shall negotiate in good faith to modify this Termination Agreement so as to effect the original intent of the Parties as closely as possible in a mutually acceptable manner in order that the transactions contemplated by this Termination Agreement be consummated as originally contemplated to the fullest extent possible.

12. Counterparts. This Termination Agreement may be executed in two or more counterparts, and by different Parties in separate counterparts, with the same effect as if all Parties had signed the same document, but all of which together shall constitute one and the same instrument. Copies of executed counterparts of this Agreement transmitted by electronic transmission (including by email or in .pdf format) or facsimile, as well as electronically or digitally executed counterparts (such as DocuSign) shall have the same legal effect as original signatures and shall be considered original executed counterparts of this Agreement.

13. Amendment. This Termination Agreement may only be amended in writing by the Parties.

Signatures on the Following Page

In Witness Whereof, the Parties have executed this Termination and Release Agreement to be duly executed as of the Termination Date.

ACQUIROR:		MERGER SUB:

BioPlus Acquisition Corp.		Guardian Merger Subsidiary Corp.

By:	/s/ Jonathan Rigby	By:	/s/ Steven Fletcher
Name:	Jonathan Rigby	Name:	Steven Fletcher
Title:	Chairman and Chief Business Officer	Title:	President and Secretary

THE COMPANY:		THE SPONSOR:

Avertix Medical, Inc. f/k/a Angel Medical Systems, Inc.		BioPlus Sponsor LLC

By:	/s/ Timothy P. Moran	By:	/s/ Steven Fletcher
Name:	Timothy P. Moran	Name:	Steven Fletcher
Title:	Chief Executive Officer	Title:	Managing Member

Exhibit 99.1

BioPlus Acquisition Corp. Announces Termination of Business Combination Agreement with Avertix Medical, Inc. and its Intention to Liquidate

New York, NY, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BioPlus Acquisition Corp. (“BIOS” or the “Company”) (Nasdaq: BIOS) announced today that (i) BIOS, Avertix Medical, Inc. and certain other parties have mutually agreed to terminate their previously announced business combination agreement and plan of reorganization (the “Business Combination Agreement”), effective as of October 4, 2023 and (ii) it intends to liquidate as soon as practicable after October 4, 2023 and to return funds to holders of its Class A ordinary shares that were included in the units issued in the Company’s initial public offering (“Public Shares”).

The Business Combination Agreement was dated as of May 2, 2023. The parties have signed an agreement terminating the Business Combination Agreement on mutually acceptable terms, which also makes void the ancillary documents to the Business Combination Agreement.

In view of the termination of the Business Combination Agreement, BIOS determined that it would be unable to consummate an initial business combination within the time period in its Amended and Restated Memorandum and Articles of Association, as amended (the “Charter”) and BIOS intends to dissolve and liquidate in accordance with the provisions of its Charter (“Liquidation”).

BIOS expects to redeem all of its Public Shares for an estimated redemption price of approximately $10.79 per share (the “Redemption Amount”) after the payment of taxes and dissolution expenses. Record holders will receive their pro rata portion of the proceeds of the trust account by delivering their Public Shares to Continental Stock Transfer & Trust Company, the Company’s transfer agent. Beneficial owners of Public Shares held in “street name,” however, will not need to take any action in order to receive the redemption amount. The redemption of the Public Shares is expected to be completed within ten business days after October 4, 2023.

The Company’s sponsor has agreed to waive its redemption rights with respect to its outstanding Class B ordinary shares issued prior to the Company’s initial public offering and the Class A ordinary shares contained in the units issued in a private placement concurrent with the initial public offering.

There will be no redemption rights or liquidating distributions with respect to the Company’s warrants, which will expire worthless.

About BioPlus Acquisition Corp.

BioPlus Acquisition Corp. was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. It is focused on identifying opportunities in the healthcare industry across the U.S., EU, Israel and Australasia.

FORWARD-LOOKING STATEMENTS

The press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements are based on various assumptions and on the current expectations of the Company’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties. A more complete discussion of the risks and uncertainties facing the Company is contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 under the heading “Risk Factors,” and other documents of the Company filed, or to be filed, with the Securities and Exchange Commission. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that the Company presently does not know or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect the Company’s expectations, plans or forecasts of future events and views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s assessments to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Contact

Ross Haghighat

Jonathan Rigby

BioPlus Acquisition Corp.

info@bioplusspac.com

Cover	Oct. 04, 2023
Document Type	8-K
Amendment Flag	false
Document Period End Date	Oct. 04, 2023
Entity File Number	001-41116
Entity Registrant Name	BIOPLUS ACQUISITION CORP.
Entity Central Index Key	0001856653
Entity Tax Identification Number	98-1583872
Entity Incorporation, State or Country Code	E9
Entity Address, Address Line One	260 Madison Avenue
Entity Address, Address Line Two	Suite 800
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10026
City Area Code	212
Local Phone Number	287-4092
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Units, each consisting of one Class A Ordinary Share and one-half of one Redeemable Warrant
Title of 12(b) Security	Units, each consisting of one Class A Ordinary Share and one-half of one Redeemable Warrant
Trading Symbol	BIOSU
Security Exchange Name	NASDAQ
Class A Ordinary Share, par value $0.0001 per share
Title of 12(b) Security	Class A Ordinary Share, par value $0.0001 per share
Trading Symbol	BIOS
Security Exchange Name	NASDAQ
Warrants, each exercisable for one Class A Ordinary Share for $11.50 per share
Title of 12(b) Security	Warrants, each exercisable for one Class A Ordinary Share for $11.50 per share
Trading Symbol	BIOSW
Security Exchange Name	NASDAQ